Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Abbott Labs reported a mixed bag of Q2 2025 earnings, showing impressive growth in some areas and facing headwinds in others. Sales grew by almost 7%, and adjusted EPS saw an 11% increase. Medical ...

Intuitive Surgical reports earnings with eyes on a 17.1% revenue increase to $2.35 billion. Last quarter, the company surpassed revenue forecasts by 3.1%, hitting $2.25 billion. Despite a mixed ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Abbott Laboratories ( NYSE: ABT) was upgraded to Buy from Hold at Jefferies following its Q2 results and revised guidance, as analysts view the market reaction as “overly punitive” and see an ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Reuters is tracking how companies are responding to the threat posed by <a href=" target="_blank" rel="noopener noreferrer nofollow">U.S. President Donald Trump’s tariffs to their operations.

Stocks like Sun Pharma, eClerx Services, Indian Energy Exchange, Anant Raj, REC, Aether Industries, Larsen & Toubro, Torrent Power, Enviro Infra Engineers, GR Infraprojects, and Adani Enterprises will ...

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.

Better-than-expected news drove the market higher this week. Inflation readings, retail sales data, unemployment claims, and consumer confidence all showed an economy that continues to outperform ...